Allergan to Present Data from 13 Abstracts at the ASDS 2018

Allergan plc, a leading global pharmaceutical company, announced that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14. The meeting will be held at the JW Marriott Desert Ridge Resort & Spa and the scheduled times (noted in local Mountain Time) of the presentations, titles and authors are as follows:

Oral presentations include:

• Safety and efficacy of onabotulinumtoxinA for treatment of masseter muscle hypertrophy: Results from a phase 2B study. Authors: Carruthers J, Liew S, et al. Thursday, October 11, 4:22 p.m.

Session OA145: Oral abstract presentations- Grand Sonoran F

• Understanding the African American facial aesthetic patient. Authors: Callendar V, Boyd C, et al. Thursday, October 11, 5:27 p.m.

Session OA145: Oral abstract presentations- Grand Sonoran F

• ATX-101 treatment among adults with mild submental fat: Data from CONTOUR. Authors: Weinkle S, Biesman B, et al. Friday, October 12, 11:22 a.m.

Session OA200: Oral abstract presentations- Grand Saguaro North-South

• Preplatysmal fat volume is reduced by approximately 25 percent among ATX-101 treatment responders: Analysis of the REFINE data. Authors: Chesnut C, Joseph J, et al. Friday, October 12 11:52 a.m.

Session OA200: Oral abstract presentations- Grand Saguaro North-South

The following posters will be on display from noon, Thursday, October 11 to 2 p.m. Saturday, October 13:

• Efficacy, safety, and patient-reported outcomes in male subjects treated with onabotulinumtoxinA for improvement of moderate to severe horizontal forehead lines. Authors: Keaney T, Cavallini M, et al.
• Efficacy and patient-reported outcomes of onabotulinumtoxinA for treatment of moderate to severe horizontal frontalis lines in millennials. Authors: Palm M, Few J, et al.
• Development of patient-reported outcome measures for masseter prominence. Authors: Fabi S, Narurkar V, et al.
• Efficacy, safety, and patient-reported outcomes following onabotulinumtoxinA treatment for moderate to severe forehead lines: A pooled analysis of two phase 3 pivotal trials. Authors: De Boulle K, Fagien S, et al.
• OnabotulinumtoxinA for the treatment of forehead and glabellar lines: patient-reported satisfaction and impact. Authors: Dayan S, Ogilvie P, et al.
• Understanding the Asian American facial aesthetic patient. Authors: Mariwalla K, Chiu A, et al.
• Understanding the Hispanic facial aesthetic patient. Authors: Bucay V, Montes JR, et al.
• Best practice for the use of ATX-101 for submental contouring. Authors: Keaney T, Schlesinger T, et al. – Medical Buyer Bureau